Keros Therapeutics (KROS) Price & Analysis

Compare

357 Followers

KROS Stock Chart & Stats

$16.83

-$0.58(-3.66%)

At close: Jan 08 4:00 PM EST

$16.83

-$0.58(-3.66%)

Day’s Range― - ―

52-Week Range$9.12 - $72.37

Previous CloseN/A

Volume109.28K

Average Volume (3M)1.19M

Market Cap

$523.41M

Enterprise Value-$33.38M

Total Cash (Recent Filing)$693.47M

Total Debt (Recent Filing)$17.43M

Price to Earnings (P/E)11.1

Beta0.58

Next Earnings

Mar 04, 2026

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding30,466,068

10 Day Avg. Volume1,226,082

30 Day Avg. Volume1,191,147

Financial Highlights & Ratios

PEG Ratio0.82

Price to Book (P/B)1.04

Price to Sales (P/S)166.94

P/FCF Ratio-3.64

Enterprise Value/Market Cap-0.06

Enterprise Value/Revenue-0.14

Enterprise Value/Gross Profit-0.14

Enterprise Value/Ebitda-0.41

Forecast

1Y Price Target

$21.00

Price Target Upside24.78% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)1.9

Revenue Forecast (FY)$244.16M

Bulls Say, Bears Say

Bulls Say

Clinical Development ProgressElritercept is now being evaluated in a Ph3 study for MDS, with the first patient dosing announced, showing progress in its clinical development.

Partnership And Financial StrengthThe partnership with Takeda is viewed as external validation of the Activin platform and a source of future upside through more than one billion in potential milestones and royalties.

Strategic FocusBy prioritizing KER-065 exclusively, Keros reduces pipeline distraction and aligns its resources behind the program with the greatest potential to create long term shareholder value.

Bears Say

Development DiscontinuationKeros will officially discontinue all development of cibotercept due to concerning pericardial effusion AEs and insufficient topline data.

Regulatory UncertaintyThere is uncertainty about the timing of the Ph2 study initiation for KER-065 as the status of discussions with regulators remains unclear.

Safety ConcernsA dose-dependent hemoglobin increase creates uncertainties in the safety profile of KER-065.

Keros Therapeutics News

Keros Therapeutics price target raised to $19 from $18 at BofA

BofA analyst Jason Zemansky raised the firm’s price target on Keros Therapeutics (KROS) to $19 from $18 and...

6d ago

KROS

Keros Therapeutics price target raised to $27 from $23 at Oppenheimer

Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Keros Therapeutics (KROS) to $27 from $23 and...

22d ago

KROS

Keros Therapeutics price target raised to $27 from $23 at Oppenheimer

Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Keros Therapeutics (KROS) to $27 from $23 and...

27d ago

KROS

Keros Therapeutics reports Q3 EPS (18c), consensus (92c)

Reports Q3 revenue $14.26M, consensus $4.22M. The net loss decrease of $45.7M was largely due to revenue recognized...

29d ago

KROS

Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Keros Therapeutics. The associated price...

28d ago

KROS

Keros Therapeutics Reports Strong Revenue Growth

Keros Therapeutics, Inc. ( ($KROS) ) has released its Q3 earnings. Here is a breakdown of the information...

28d ago

KROS

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties

William Blair analyst Matt Phipps has maintained their neutral stance on KROS stock, giving a Hold rating yesterday....

28d ago

KROS

Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating

TD Cowen analyst Tyler Van Buren has maintained their neutral stance on KROS stock, giving a Hold rating...

28d ago

KROS

Keros Therapeutics to repurchase $194.4M of shares

Keros Therapeutics (KROS) announced that, as part of its previously announced $375M capital return program, it has commenced...

2M ago

KROS

Keros Therapeutics Announces $375M Capital Return Program

The latest announcement is out from Keros Therapeutics ( ($KROS) ). On October 15, 2025, Keros Therapeutics announced...

2M ago

KROS

Keros Therapeutics announces share repurchase program

Keros Therapeutics (KROS) announced that, as part of its previously announced $375M capital return program, it has entered...

2M ago

TAK

KROS

Keros Therapeutics Presents Promising Phase 1 Trial Data

Keros Therapeutics ( ($KROS) ) has provided an update. On September 8, 2025, Keros Therapeutics announced the presentation...

3M ago

KROS

Keros Therapeutics presents additional clinical data from KER-065 program

Keros Therapeutics (KROS) presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male...

3M ago

KROS

Keros Therapeutics CEO to Speak at Healthcare Conferences

An update from Keros Therapeutics ( ($KROS) ) is now available. On August 28, 2025, Keros Therapeutics announced...

3M ago

KROS

KROS FAQ

What was Keros Therapeutics’s price range in the past 12 months?

Keros Therapeutics lowest stock price was $9.12 and its highest was $72.37 in the past 12 months.

What is Keros Therapeutics’s market cap?

Keros Therapeutics’s market cap is $523.41M.

When is Keros Therapeutics’s upcoming earnings report date?

Keros Therapeutics’s upcoming earnings report date is Mar 04, 2026 which is in 90 days.

How were Keros Therapeutics’s earnings last quarter?

Keros Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$1.135 by $0.955.

Is Keros Therapeutics overvalued?

According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Keros Therapeutics pay dividends?

Keros Therapeutics does not currently pay dividends.

What is Keros Therapeutics’s EPS estimate?

Keros Therapeutics’s EPS estimate is -0.7.

How many shares outstanding does Keros Therapeutics have?

Keros Therapeutics has 30,466,068 shares outstanding.

What happened to Keros Therapeutics’s price movement after its last earnings report?

Keros Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$1.135. Following the earnings report the stock price went up 3.323%.

Which hedge fund is a major shareholder of Keros Therapeutics?

Currently, no hedge funds are holding shares in KROS

Keros Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

10.43%

Trailing 12-Months

Asset Growth

28.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Keros Therapeutics

Keros Therapeutics, Inc. (KROS) is a biotechnology company focused on developing innovative therapies for rare hematological and endocrine disorders. The company is engaged in the discovery and development of novel treatments that target the pathways involved in these conditions, with core products aimed at addressing unmet medical needs in conditions such as anemia and other related disorders.

Keros Therapeutics (KROS) Earnings & Revenues

Historic Earnings Reports

KROS Stock 12 Month Forecast

Average Price Target

$21.00

▲(24.78% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","21":"$21","34":"$34","47":"$47","60":"$60"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,21,34,47,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.22,16.126153846153848,17.032307692307693,17.93846153846154,18.844615384615384,19.75076923076923,20.65692307692308,21.563076923076924,22.46923076923077,23.375384615384615,24.28153846153846,25.18769230769231,26.09384615384615,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.22,15.664615384615384,16.10923076923077,16.553846153846155,16.998461538461537,17.443076923076923,17.88769230769231,18.332307692307694,18.776923076923076,19.22153846153846,19.666153846153847,20.11076923076923,20.555384615384614,{"y":21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.22,15.280000000000001,15.34,15.4,15.46,15.52,15.58,15.64,15.700000000000001,15.76,15.82,15.88,15.94,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":59.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >